PT - JOURNAL ARTICLE AU - Paul J. Rathouz AU - Victoria Valencia AU - Patrick Chang AU - David Morton AU - Haoxiang Yang AU - Ozge Surer AU - Spencer Fox AU - Lauren Ancel Meyers AU - Elizabeth C. Matsui AU - Alex B. Haynes TI - Survival analysis methods for analysis of hospitalization data: Application to COVID-19 patient hospitalization experience AID - 10.1101/2021.04.14.21255511 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.14.21255511 4099 - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255511.short 4100 - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255511.full AB - During most of 2020, the COVID-19 pandemic gave rise to considerable and growing numbers of hospitalizations across most of the U.S. Typical COVID-19 hospitalization data, including length of stay, intensive care unit (ICU) use, mechanical ventilation (Vent), and in-hospital mortality provide clearly interpretable health care endpoints that can be compared across population strata. They capture the resources consumed for the care of COVID-19 patients, and analysis of these endpoints can be used for resource planning at the local level. Yet, hospitalization data embody novel features that require careful statistical treatment to be useful in this context. Specifically, statistical models must meet three goals: (i) They should mesh with and inform mathematical epidemiologic or agent-based models of the COVID-19 experience in the population. (ii) They need to handle administrative censoring of hospitalization experience when data are extracted and downloaded for a given patient before that patient’s hospitalization experience has terminated. And, (iii) models need to handle risks for competing events, the occurrence of one blocking the possibility of the other(s). For example, live discharge from the hospital “competes with” (i.e., blocks) in-hospital mortality. We have adapted approaches from the survival analysis literature to address these challenges in order to better understand and quantify the population experience in hospital with respect to length of stay, ICU, Vent use and so on. Using hospitalization data from a large U.S. metropolitan region, in this report, we show how standard techniques from survival analysis can be brought to bear to address these challenges and yield interpretable results. In the breakout/discussion, we will discuss formulation, estimation and inference, and interpretation of competing risks models.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a trial.Funding StatementLabor and other resources for this study were internally funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Minimal risk human subjects research approved by the UT Austin IRB (A Haynes, PI)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThese data are not available for distribution.